Cannon Global Investment Management LLC Acquires New Stake in Kiniksa Pharmaceuticals International, plc $KNSA

by · The Markets Daily

Cannon Global Investment Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Free Report) in the first quarter, Holdings Channel reports. The firm acquired 11,000 shares of the company’s stock, valued at approximately $530,000.

Several other hedge funds have also added to or reduced their stakes in the stock. Smartleaf Asset Management LLC purchased a new stake in Kiniksa Pharmaceuticals International during the 4th quarter valued at about $36,000. EverSource Wealth Advisors LLC raised its holdings in Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after buying an additional 532 shares during the last quarter. Nano Cap New Millennium Growth Fund L P bought a new position in shares of Kiniksa Pharmaceuticals International in the fourth quarter worth approximately $41,000. CIBC Private Wealth Group LLC bought a new position in shares of Kiniksa Pharmaceuticals International in the fourth quarter worth approximately $41,000. Finally, Quarry LP purchased a new stake in shares of Kiniksa Pharmaceuticals International during the third quarter valued at approximately $44,000. 53.95% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Zacks Research raised shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, June 17th. Wells Fargo & Company upped their price objective on Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an “overweight” rating in a research report on Wednesday, April 29th. Jefferies Financial Group lifted their target price on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Wedbush boosted their price target on Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 29th. Finally, Citigroup increased their price objective on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International presently has a consensus rating of “Buy” and an average target price of $60.86.

Check Out Our Latest Report on KNSA

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CAO Michael R. Megna sold 6,625 shares of the business’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $46.69, for a total transaction of $309,321.25. Following the completion of the sale, the chief accounting officer directly owned 27,418 shares in the company, valued at $1,280,146.42. The trade was a 19.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry D. Quart sold 13,099 shares of the company’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $50.10, for a total transaction of $656,259.90. Following the sale, the director directly owned 12,546 shares of the company’s stock, valued at $628,554.60. The trade was a 51.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 653,301 shares of company stock worth $34,046,073. 51.98% of the stock is owned by corporate insiders.

Kiniksa Pharmaceuticals International Price Performance

KNSA stock opened at $59.20 on Friday. Kiniksa Pharmaceuticals International, plc has a 1 year low of $26.27 and a 1 year high of $61.12. The company has a market cap of $4.55 billion, a P/E ratio of 65.78 and a beta of 0.12. The stock’s fifty day moving average price is $52.17 and its 200-day moving average price is $46.95.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The company had revenue of $214.27 million during the quarter, compared to analysts’ expectations of $206.11 million. During the same quarter in the prior year, the business earned $0.11 earnings per share. Kiniksa Pharmaceuticals International’s revenue for the quarter was up 55.5% compared to the same quarter last year. As a group, analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.24 earnings per share for the current year.

About Kiniksa Pharmaceuticals International

(Free Report)

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.

Recommended Stories

Want to see what other hedge funds are holding KNSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Free Report).